Cleo Capital

Cleo Capital is a US-based early-stage venture firm founded by Sarah Kunst, with a generalist software, consumer, and selective healthcare thesis. The firm’s positioning emphasizes founder-friendly, network-rich seed investing, with a particular eye on diverse founders, women founders, and companies serving underserved markets. Healthcare exposure exists but is not the headline thesis, so founders should treat Cleo as a generalist seed co-investor whose value-add is operator network, brand, and visibility rather than clinical or regulatory specialization. Stage focus is pre-seed and seed, with check sizes plausibly $100K to $750K and a willingness to participate in primary-led rounds. Founders who should approach: pre-seed and seed-stage healthcare AI teams in mental health, women’s health, employer health, consumer health, and community-driven care models; founders who would benefit from Cleo’s media presence and operator network; teams building category-creating consumer-facing health products. Founders who should not approach: regulated medical devices, biotech, and clinical AI selling exclusively into hospitals where Cleo cannot add domain-specialist value. Their value-add is brand visibility, operator relationships, and a strong female-founder community that has become a meaningful sourcing and support network. Entry path is warm introduction through portfolio founders, the broader female-founder VC network (Ada Ventures, Halogen, Female Founders Fund), or LinkedIn outreach with a thesis-fit articulation. Their LinkedIn and website are active and accessible. Be prepared to discuss founder story, market positioning, and brand narrative — Cleo invests with a clear sensitivity to founder voice and category framing.